Nivolumab + Temozolomide
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Brain Neoplasms
Conditions
Brain Neoplasms
Trial Timeline
May 9, 2016 → Apr 9, 2024
NCT ID
NCT02667587About Nivolumab + Temozolomide
Nivolumab + Temozolomide is a phase 3 stage product being developed by Ono Pharmaceutical for Brain Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT02667587. Target conditions include Brain Neoplasms.
What happened to similar drugs?
5 of 17 similar drugs in Brain Neoplasms were approved
Approved (5) Terminated (2) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02667587 | Phase 3 | Completed |
| NCT02617589 | Phase 3 | Completed |
Competing Products
20 competing products in Brain Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Endocrine therapy | Eli Lilly | Phase 1/2 | 39 |
| Duloxetine + Sugar pill | Eli Lilly | Phase 2 | 27 |
| Neurosteroid enantiomer | Oragenics | Phase 2 | 32 |
| Patritumab deruxtecan | Daiichi Sankyo | Phase 2 | 27 |
| filgrastim + exatecan mesylate | Daiichi Sankyo | Phase 1 | 29 |
| Eribulin Mesylate | Eisai | Phase 1 | 29 |
| Pembrolizumab + Lenvatinib | Eisai | Phase 2 | 42 |
| Palonosetron (Aloxi) and Dexamethasone | Eisai | Phase 2 | 27 |
| GLIADEL | Eisai | Phase 2 | 35 |
| Nivolumab + Temozolomide | Ono Pharmaceutical | Phase 3 | 40 |
| Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim | Eli Lilly | Phase 1 | 29 |
| abemaciclib + abemaciclib | Eli Lilly | Phase 2 | 39 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 27 |
| ABT-888 | AbbVie | Phase 1 | 29 |
| Veliparib + Placebo | AbbVie | Phase 2 | 35 |
| Iressa (Gefitinib) | AstraZeneca | Phase 2 | 27 |
| Trastuzumab deruxtecan | AstraZeneca | Phase 2 | 42 |
| Exenatide | AstraZeneca | Approved | 43 |
| AZD5213 | AstraZeneca | Phase 1 | 29 |
| Vorinostat | Merck | Phase 1 | 29 |